Skip to main content
. 2021 Jun 22;11(16):7735–7754. doi: 10.7150/thno.60757

Figure 6.

Figure 6

Dual cancer-osteoclast RaST in mice. (A) Fox Chase SCID beige MM1.S xenograft animals untreated or treated once weekly for five weeks with αvß3-TC-NM RaST, VLA-4-TC-NM RaST, and αvβ3-TC-NM + VLA-4-TC-NM RaST; MM1.S/CBR/GFP cells (1 x 106 cells per animal) were implanted IV and the therapy was initiated after the whole body radiance reached 1 x 106 photons/sec/cm2/steradian (p/s/cm2/sr). Tumor progression was monitored with weekly BLI. αvβ3-TC-NM + VLA-4-TC-NM RaST significantly reduced tumor progression compared to no treatment (P = 0.0007). (B) Representative bioluminescence images of Fox Chase SCID beige MM1.S xenograft animals treated with αvβ3-TC-NM + VLA-4-TC-NM RaST and the untreated controls. (C) C57BL/6-KaLwRij 5TGM isograft animals were implanted with 5TGM/CBR/GFP cells (1 x 106 cells per animal) and monitored as in (A). The test animals were untreated or treated once weekly for five weeks with αvβ3-TC-NM RaST, VLA-4-TC-NM RaST, and αvβ3-TC-NM + VLA-4-TC-NM RaST. αvβ3-TC-NM + VLA-4-TC-NM RaST significantly inhibited tumor progression compared to no treatment (P = 0.0317). (D) Representative bioluminescence images of C57BL/6-KaLwRij 5TGM isograft animals treated with αvβ3-TC-NM + VLA-4-TC-NM RaST and the untreated controls. Two-way ANOVA and Tukey's multiple comparisons were used for the statistical analysis.